Logo image of MLTX

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Fundamental Analysis

NASDAQ:MLTX - Nasdaq - KY61559X1045 - Common Stock - Currency: USD

44.11  +0.46 (+1.05%)

After market: 44.11 0 (0%)

Fundamental Rating

3

Taking everything into account, MLTX scores 3 out of 10 in our fundamental rating. MLTX was compared to 572 industry peers in the Biotechnology industry. MLTX has a great financial health rating, but its profitability evaluates not so good. MLTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MLTX has reported negative net income.
MLTX had a negative operating cash flow in the past year.
MLTX had negative earnings in each of the past 5 years.
In the past 5 years MLTX always reported negative operating cash flow.
MLTX Yearly Net Income VS EBIT VS OCF VS FCFMLTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

With an excellent Return On Assets value of -15.59%, MLTX belongs to the best of the industry, outperforming 82.30% of the companies in the same industry.
With an excellent Return On Equity value of -16.54%, MLTX belongs to the best of the industry, outperforming 87.79% of the companies in the same industry.
Industry RankSector Rank
ROA -15.59%
ROE -16.54%
ROIC N/A
ROA(3y)-208.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MLTX Yearly ROA, ROE, ROICMLTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MLTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLTX Yearly Profit, Operating, Gross MarginsMLTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, MLTX has more shares outstanding
MLTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MLTX Yearly Shares OutstandingMLTX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M
MLTX Yearly Total Debt VS Total AssetsMLTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 55.70 indicates that MLTX is not in any danger for bankruptcy at the moment.
MLTX has a Altman-Z score of 55.70. This is amongst the best in the industry. MLTX outperforms 98.58% of its industry peers.
MLTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 55.7
ROIC/WACCN/A
WACCN/A
MLTX Yearly LT Debt VS Equity VS FCFMLTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

MLTX has a Current Ratio of 25.51. This indicates that MLTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 25.51, MLTX belongs to the best of the industry, outperforming 96.81% of the companies in the same industry.
A Quick Ratio of 25.51 indicates that MLTX has no problem at all paying its short term obligations.
MLTX has a better Quick ratio (25.51) than 96.81% of its industry peers.
Industry RankSector Rank
Current Ratio 25.51
Quick Ratio 25.51
MLTX Yearly Current Assets VS Current LiabilitesMLTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MLTX have decreased strongly by -35.79% in the last year.
EPS 1Y (TTM)-35.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.07% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-134.19%
EPS Next 2Y-88.47%
EPS Next 3Y-63.48%
EPS Next 5Y13.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLTX Yearly Revenue VS EstimatesMLTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
MLTX Yearly EPS VS EstimatesMLTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLTX Price Earnings VS Forward Price EarningsMLTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLTX Per share dataMLTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as MLTX's earnings are expected to decrease with -63.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-88.47%
EPS Next 3Y-63.48%

More info and screens

0

5. Dividend

5.1 Amount

MLTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ:MLTX (2/4/2025, 8:00:01 PM)

After market: 44.11 0 (0%)

44.11

+0.46 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners96.4%
Inst Owner Change0%
Ins Owners10.56%
Ins Owner Change-26.27%
Market Cap2.82B
Analysts84.35
Price Target80.86 (83.31%)
Short Float %14.55%
Short Ratio23.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.01%
Min EPS beat(2)-37.92%
Max EPS beat(2)-26.1%
EPS beat(4)1
Avg EPS beat(4)-6.67%
Min EPS beat(4)-37.92%
Max EPS beat(4)48.88%
EPS beat(8)5
Avg EPS beat(8)5.68%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.35%
PT rev (3m)8.81%
EPS NQ rev (1m)2.56%
EPS NQ rev (3m)-43.21%
EPS NY rev (1m)1.71%
EPS NY rev (3m)-11.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.77
P/tB 5.77
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-2.7
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.26
OCFYN/A
SpS0
BVpS7.64
TBVpS7.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.59%
ROE -16.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-208.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.51
Quick Ratio 25.51
Altman-Z 55.7
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.11%
EPS Next Y-134.19%
EPS Next 2Y-88.47%
EPS Next 3Y-63.48%
EPS Next 5Y13.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-94.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-135.21%
EBIT Next 3Y-64.81%
EBIT Next 5YN/A
FCF growth 1Y-56.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.45%
OCF growth 3YN/A
OCF growth 5YN/A